+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of AZD1163, a novel bispecific antibody, in adults with moderately-to-severely active rheumatoid arthritis RA. AZD1163 targets enzymes involved in protein citrullination, which leads to the production of harmful antibodies in RA. This Phase II, randomized, double-blind, placebo-controlled study focuses on adults with positive anti-citrullinated peptide antibodies ACPA who are already receiving standard treatments. Participants will be randomly assigned to one of four groups to receive subcutaneous injections of either one of three doses of AZD1163 or a placebo, all combined with their standard care including conventional synthetic disease-modifying antirheumatic drugs csDMARDs or tumor necrosis factor inhibitors TNFi with or without csDMARDs. The treatment period lasts 24 weeks, followed by a safety follow-up phase of 28 weeks. During the study, participants will undergo assessments including measures of disease activity using scores such as DAS28-CRP at 12 weeks. Additional evaluations will monitor response criteria, clinical disease activity indices, and the pharmacokinetics and immunogenicity of AZD1163 up to 24 weeks and during follow-up. Safety and efficacy will be closely monitored throughout the treatment and follow-up periods, with total participation lasting approximately 52 weeks.

Age: 18Years +All GendersPhase 2
147 locations
S

Actively Recruiting

Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.

Age: 18Years +All GendersPhase 4
264 locations